scholarly journals Preliminary results of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in stage II-IV rectal cancer

2020 ◽  
Author(s):  
Mehmet Salih İYİKESİCİ
Keyword(s):  
Rectal Cancer ◽  
Ketogenic Diet ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Stage Ii ◽  
Preliminary Results

scholarly journals Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer

2019 ◽  
Vol 27 (1) ◽  
pp. 31-39 ◽  
Author(s):  
Mehmet Salih Iyikesici
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Ketogenic Diet ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Metastatic Pancreatic Cancer ◽  
Survival Outcomes ◽  
Pancreatic Ductal Carcinoma ◽  
Term Survival

Background: Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell. Objectives: This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer. Method: This retrospective observational study included 25 patients with metastatic pancreatic ductal carcinoma (stage IV) who received MSCT (either gemcitabine-based or FOLFIRINOX regimen administered concomitantly with induced hypoglycemia) plus ketogenic diet, hyperthermia, and HBOT combination. Survival outcomes were evaluated. Results: During the mean follow-up duration of 25.4 ± 19.3 months, median overall survival and median progression-free survival were 15.8 months (95% CI, 10.5–21.1) and 12.9 months (95% CI, 11.2–14.6), respectively. Age and gender did not have any effect on overall survival (p > 0.05 for all). Conclusions: MSCT administered together with ketogenic diet, hyperthermia, and HBOT appears to be a viable option with the potential to improve survival outcomes in patients diagnosed with metastatic pancreatic cancer. Further research, particularly with larger comparative clinical trials, is warranted.

Su1767 - Hyperbaric Oxygen Therapy Enhances the Effect of 5-Fluorouracil in a Rectal Cancer Model

2018 ◽  
Vol 154 (6) ◽  
pp. S-583
Author(s):  
Vanessa Foresto Machado Leal ◽  
Marley R. Feitosa ◽  
Rogerio Serafim Parra ◽  
Jose Henrique Silvah ◽  
Letícia C. Ribeiro ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Cancer Model

scholarly journals The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. e65522 ◽  
Author(s):  
Angela M. Poff ◽  
Csilla Ari ◽  
Thomas N. Seyfried ◽  
Dominic P. D’Agostino
Keyword(s):  
Ketogenic Diet ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Metastatic Cancer
Sign in / Sign up

Export Citation Format

Share Document